BioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...
Vaccines Market Size, Top Share, Forecast To 2033
Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
DelveInsight Business Research, LLP: ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
Market Inference3h
AT&T (T) Investors – Latest News Update
Shares of Telecommunications sector company AT&T moved 2.7% today, and are now trading at a price of $26.41. The Large-Cap ...